Viewing Study NCT00004464



Ignite Creation Date: 2024-05-05 @ 10:00 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004464
Status: COMPLETED
Last Update Posted: 2019-01-18
First Post: 1999-10-18

Brief Title: Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Overview

Official Title: High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Status: COMPLETED
Status Verified Date: 2018-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES I Confirm the efficacy demonstrated in a pilot study using high dose cyclophosphamide in patients with severe aplastic anemia

II Determine whether the addition of filgrastim G-CSF to high dose cyclophosphamide shortens the time to recovery in these patients

III Determine whether this regimen is efficacious in treating paroxysmal nocturnal hemoglobinuria
Detailed Description: PROTOCOL OUTLINE Patients receive high dose cyclophosphamide IV on days 1-4 Beginning on day 10 patients receive filgrastim G-CSF until the absolute neutrophil count is greater than 1000mm3 for 2 consecutive days

Patients are followed every 3 months for at least 2 years and annually thereafter

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
96-01-17-02 OTHER None None
JHOC-96011702 None None None
JHOC-9611 OTHER None None
19913895 OTHER other None